We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CytRx Preparing to Resubmit Trial Protocol for ALS Drug
CytRx Preparing to Resubmit Trial Protocol for ALS Drug
September 16, 2009
The FDA will allow CytRx to resubmit the protocol for its planned Phase IIb clinical trial of arimoclomol for amyotrophic lateral sclerosis (ALS), after the agency imposed a clinical hold on the study.